Igc Pharma Inc (IGC) Stock Price, Quote & News

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease in India, the United States, and Colombia. The company's lead product is IGC-AD1, which is in Phase 2 clinical trial for the treatment of agitation in dementia due to Alzheimer's; and TGR-63, IGC-M3, and LMP that are in pre-clinical stage for the treatment of Alzheimer's disease. It also develops IGC-1A and IGC-1C which are in pre-clinical stage for the treatment of metabolic disor...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 983 0998

Website: igcpharma.com

Address:

10224 Falls Road, Potomac, United States

nsosis Jul. 17 at 7:24 PM

$IGC 5% up wowwww 😆

1 · Reply

Tom678 Jul. 17 at 6:38 PM

$IGC looking really bullish

0 · Reply

Ottersberger Jul. 17 at 4:48 PM

$IGC bought another 10K - let’s see if it pays out…

0 · Reply

FeliciaMath Jul. 17 at 3:54 PM

bought $IGC at .35

0 · Reply

DARKP00L Jul. 17 at 2:50 PM

$IGC the market is buzzing about this stock. Expect possible price changes!

0 · Reply

matthewboyntonbeach Jul. 17 at 2:43 PM

$IGC float looks locked $3 in a heartbeat

0 · Reply

Tom678 Jul. 17 at 2:38 PM

$IGC only way up now, expecting more great news

0 · Reply

gen_y_stocker Jul. 17 at 2:31 PM

$IGC time to go ⬆️

0 · Reply

DARKP00L Jul. 17 at 2:24 PM

$IGC this stock is seeing a surge in interest. Market volatility might ensue!

0 · Reply

oii Jul. 17 at 2:16 PM

$IGC only up from here

0 · Reply

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

Jun 30, 2025, 9:00 AM EDT - 17 days ago

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

Jun 27, 2025, 8:30 AM EDT - 20 days ago

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

Jun 23, 2025, 8:30 AM EDT - 24 days ago

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

May 22, 2025, 9:30 AM EDT - 2 months ago

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

May 12, 2025, 9:30 AM EDT - 2 months ago

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

Apr 24, 2025, 9:30 AM EDT - 3 months ago

IGC Pharma Welcomes Strategic Investment from Advisors

Apr 21, 2025, 9:30 AM EDT - 3 months ago

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

Apr 8, 2025, 9:30 AM EDT - 3 months ago

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

Apr 1, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

Mar 26, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

Mar 20, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

Mar 17, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

Mar 12, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.

Mar 10, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

Mar 4, 2025, 9:00 AM EST - 4 months ago

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

Feb 20, 2025, 9:00 AM EST - 5 months ago

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

Feb 18, 2025, 8:30 AM EST - 5 months ago

IGC Pharma Reports Third Quarter Fiscal 2025 Results

Feb 11, 2025, 8:30 AM EST - 5 months ago

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

Jan 28, 2025, 8:30 AM EST - 6 months ago

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

Jan 13, 2025, 8:30 AM EST - 6 months ago

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

Jan 8, 2025, 8:30 AM EST - 6 months ago

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

Dec 19, 2024, 7:00 PM EST - 7 months ago

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025

Dec 2, 2024, 8:30 AM EST - 8 months ago

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

Nov 25, 2024, 8:30 AM EST - 8 months ago

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

Nov 14, 2024, 8:30 AM EST - 8 months ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline

Nov 6, 2024, 8:30 AM EST - 9 months ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies

Oct 17, 2024, 8:30 AM EDT - 9 months ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

Oct 3, 2024, 9:00 AM EDT - 10 months ago

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge

Sep 18, 2024, 8:00 AM EDT - 10 months ago

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

Sep 4, 2024, 8:00 AM EDT - 11 months ago

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

Aug 22, 2024, 9:00 AM EDT - 11 months ago

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

Aug 8, 2024, 9:30 PM EDT - 1 year ago

IGC Pharma Reports First Quarter Fiscal 2025 Results

Jul 18, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target

Jul 9, 2024, 9:10 AM EDT - 1 year ago

Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

Jun 25, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease

Jun 10, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol

May 28, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1

May 21, 2024, 2:00 PM EDT - 1 year ago

IGC Pharma to Attend BIO International Convention 2024

Apr 16, 2024, 7:00 AM EDT - 1 year ago

IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two

Apr 9, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Adds Advisor in Artificial Intelligence

Mar 26, 2024, 3:00 PM EDT - 1 year ago

IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

Mar 20, 2024, 11:00 AM EDT - 1 year ago

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation

Mar 20, 2024, 7:00 AM EDT - 1 year ago

IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024

Mar 12, 2024, 3:00 PM EDT - 1 year ago

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline

Feb 23, 2024, 12:01 PM EST - 1 year ago

IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target

Feb 16, 2024, 7:05 PM EST - 1 year ago

IGC Pharma Reports Third Quarter Fiscal 2024 Results

Feb 1, 2024, 9:20 AM EST - 1 year ago

IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model

Jan 23, 2024, 9:20 AM EST - 1 year ago

IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's

Jan 17, 2024, 9:20 AM EST - 1 year ago

IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial

nsosis Jul. 17 at 7:24 PM

$IGC 5% up wowwww 😆

1 · Reply

Tom678 Jul. 17 at 6:38 PM

$IGC looking really bullish

0 · Reply

Ottersberger Jul. 17 at 4:48 PM

$IGC bought another 10K - let’s see if it pays out…

0 · Reply

FeliciaMath Jul. 17 at 3:54 PM

bought $IGC at .35

0 · Reply

DARKP00L Jul. 17 at 2:50 PM

$IGC the market is buzzing about this stock. Expect possible price changes!

0 · Reply

matthewboyntonbeach Jul. 17 at 2:43 PM

$IGC float looks locked $3 in a heartbeat

0 · Reply

Tom678 Jul. 17 at 2:38 PM

$IGC only way up now, expecting more great news

0 · Reply

gen_y_stocker Jul. 17 at 2:31 PM

$IGC time to go ⬆️

0 · Reply

DARKP00L Jul. 17 at 2:24 PM

$IGC this stock is seeing a surge in interest. Market volatility might ensue!

0 · Reply

oii Jul. 17 at 2:16 PM

$IGC only up from here

0 · Reply

Guanabo498 Jul. 17 at 2:01 PM

$IGC

0 · Reply

Tom678 Jul. 17 at 12:09 PM

$IGC holding the gem 💎

0 · Reply

Jjjujugg Jul. 17 at 8:04 AM

$IGC scam stock

0 · Reply

counter Jul. 17 at 1:50 AM

$IGC they better get the fuck out there and do damage repair before i unleash... $MULN $CENN...Terry McAuliffe

0 · Reply

counter Jul. 17 at 1:13 AM

$IGC $MULN $CENN

0 · Reply

counter Jul. 17 at 1:12 AM

$IGC hey Terry McAuliffe...hows $CENN & $MULNDOING these days? https://finance.yahoo.com/news/fraud-charges-lost-patents-l-164221622.html?_guc_consent_skip=1752705856

0 · Reply

counter Jul. 17 at 12:49 AM

$IGC hey...Terry McAuliffe ...how things turn out? https://kpic.com/amp/news/local/car-companys-big-plans-havent-come-to-fruition-11-13-2015 $CENN $MULN

0 · Reply

counter Jul. 17 at 12:44 AM

$IGC for those that can read....rob you blind language...https://www.sohu.com/a/355142764_109560...trust me, its all connected

0 · Reply

counter Jul. 17 at 12:38 AM

$IGC shall we talk about the old $MULN days Terry McAuliffe? $CENN

0 · Reply

counter Jul. 16 at 11:47 PM

$IGC hey...Terry McAuliffe...another trickle...."Saleene+ $MULN Former U.S. Assistant Secretary of Transportation Marianne McInerney joins Saleen Automotive 2019-11-21 14:20 530 On November 21, 2019, Saleen, the pioneer of American supercars and the global leader of supercars, announced today that former U.S. Assistant Secretary of Transportation and Director of Public Affairs Marianne McInerney has joined Saleen Automotive as the President of Global Marketing, fully responsible for the company's marketing strategy planning, brand building, resource integration, and marketing work in core markets including the United States, Europe and China. Ms. Marianne McInerney is a member of Saleen Automotive's Management Committee and reports directly to Dr. Xiaolin Wang, Chairman and CEO of Saleen Automotive.

0 · Reply

counter Jul. 16 at 11:34 PM

$IGC Im getting tired of waiting....going to start slowly releasing all my info on board of director Terry McAuliffe ...im going to trickle non stop https://www.washingtontimes.com/news/2013/aug/4/with-no-record-of-defense-department-approval-mcau/

0 · Reply

counter Jul. 16 at 11:21 PM

$IGC btw....you may also want to ask this guy whats going on...https://x.com/TerryMcAuliffe... I have an ENDLESS HUGE file collected on him and his doings over the years...linked with $CENN ... $MULN is in the mix...Ive spent almost 5 years tracking what this guys been doing....hes a board of directors now on ICG....Im sure they read these board....so...Terry...stop playing games....or ill let my entire file on you go public

1 · Reply

Market Cap	27.06M
Revenue (ttm)	1.27M
Net Income (ttm)	-7.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-560.63%
Debt to Equity Ratio	0.02

Volume	806,230
Avg Vol	2,964,688
Day's Range	N/A - N/A
Shares Out	79.69M
Stochastic %K	20%
Beta	1.45
Analysts	Sell
Price Target	$3.88